Related Experiment Video
Updated: Jan 21, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
Published on: October 25, 2024
The Occurrence of Metronidazole-Induced Encephalopathy in Cancer Patients: A Hospital-Based Retrospective Study
Jui-Ping Tsai1,2, Kevin Li-Chun Hsieh2,3,4, Tu-Hsueh Yeh1,2,5
1Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan.
Background:
Metronidazole-induced encephalopathy (MIE) is a rare but serious complication caused by metronidazole, a widely used antianaerobic drug. Previous studies prescribed MIE including dysarthria, cerebellar ataxia, and confusion after long-term use of metronidazole. Malignancy has been proposed one of the predisposing conditions for MIE. However, the occurrence of MIE in cancer patients remains unknown.
Methodology:
We investigated the occurrence of MIE and analyzed retrospectively by hospital-based data of 4160 cancer patients from January 2014 to December 2016.
Results:
Findings in 793 cancer patients who underwent metronidazole therapy for anaerobic infection revealed two cases of MIE. One had renal cell carcinoma and the other had bladder urothelial carcinoma. Both of their initial presentation were cerebellar dysfunction. The occurrence of MIE was 8.6% for cases who received >30 g of cumulative dose. Hypertension was the most common comorbidity, followed by chronic renal disease and diabetes mellitus.
Conclusion:
In cancer patients, MIE should be monitored in those with genitourinary cancer, especially with renal dysfunction. Longer duration with more cumulative dose also has a greater risk of MIE. Early consideration of MIE with prompt cessation of metronidazole may result in better outcome.
Insights
Metronidazole-induced encephalopathy (MIE) is a rare complication in cancer patients. Monitoring is recommended for genitourinary cancer patients, especially those with renal dysfunction, to improve outcomes.
Area of Science:
- Neurology
- Oncology
- Infectious Diseases
Background:
- Metronidazole-induced encephalopathy (MIE) is a rare but serious complication of metronidazole, an antianaerobic drug.
- Previous studies noted MIE symptoms like cerebellar ataxia and confusion, often after prolonged metronidazole use.
- Malignancy has been suggested as a predisposing factor, but MIE occurrence in cancer patients was unknown.
Purpose of the Study:
- To investigate the occurrence of MIE in cancer patients.
- To identify risk factors and clinical characteristics of MIE in this population.
Main Methods:
- Retrospective analysis of hospital-based data from 4160 cancer patients.
- Focus on 793 patients who received metronidazole therapy for anaerobic infections between January 2014 and December 2016.
Main Results:
- Two cases of MIE were identified among 793 cancer patients treated with metronidazole.
- Both MIE cases involved genitourinary cancers (renal cell carcinoma and bladder urothelial carcinoma) and presented with cerebellar dysfunction.
- MIE occurrence was 8.6% in patients receiving >30 g cumulative metronidazole dose.
- Common comorbidities included hypertension, chronic renal disease, and diabetes mellitus.
Conclusions:
- MIE should be monitored in cancer patients, particularly those with genitourinary cancers and renal dysfunction.
- Increased duration and cumulative dose of metronidazole correlate with a higher risk of MIE.
- Early recognition and prompt discontinuation of metronidazole may lead to better patient outcomes.
Related Concept Videos
Hospitals-II
Nurses that work in...
Hospitals-I
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Mechanisms of Retrovirus-induced Cancers
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Bioavailability Study Design: Healthy Subjects Versus Patients

